Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder

BACKGROUND: Fluvoxamine therapy is used for treatment of patients with depressive disorder, but it is often ineffective, and some patients suffer from dose-dependent undesirable side effects such as vertigo, headache, indigestion, xerostomia, increased anxiety, etc. CYP2D6 is involved in the biotran...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pharmgenomics Pers Med
Auteurs principaux: Zastrozhin, Mikhail Sergeevich, Grishina, Elena Anatolievna, Denisenko, Nataliya Petrovna, Skryabin, Valentin Yurievich, Markov, Dmitry Dmitrievich, Savchenko, Ludmila Mikhailovna, Bryun, Evgeny Alekseevich, Sychev, Dmitry Alekseevich
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2018
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6029588/
https://ncbi.nlm.nih.gov/pubmed/29988737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S160763
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires